Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy

NCT02208843 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02208843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02208843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
October 2, 2014
Completion date
June 13, 2017
Enrollment
60 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung